October 13, 2016

Data Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies reinforcing the clinical impact and value of the company's Percepta[®] Bronchial Genomic Classifier and Envisia™ Genomic Classifier - for use in lung cancer and idiopathic pulmonary fibrosis (IPF) diagnosis, respectively - at the CHEST Annual Meeting 2016, being held October 22-26 in Los Angeles.

During the meeting, external researchers will also share data evaluating the ability of the Envisia classifier to enable improved diagnosis of IPF.

"The findings being presented at this year's CHEST meeting highlight our continued focus on both developing advanced genomic classifiers that have a tangible, positive impact on patient care and securing the clinical evidence that gives physicians and insurers the confidence they need to adopt these valuable diagnostic tests," said Bonnie Anderson, Veracyte's president and chief executive officer.

Following is a summary of the abstracts that will be presented at CHEST 2016*:

Title:	Impact of a Bronchial Genomic Classifier for Lung Cancer on Reducing Invasive Procedure Recommendations Across Variations in Pulmonology Practices (Session 4030)
Presenter:	Ryan Van Wert, M.D. (Stanford University)
Date/Time:	Sunday, October 23, 5:15-5:30 p.m.

Title:	Understanding the Patient Journey of Interstitial Lung Disease Diagnosis: The INTENSITY Survey (Session 4150)
Presenter:	Gregory P. Cosgrove, M.D. (National Jewish Health)
Date/Time:	Wednesday, October 26, 8:45-9:00 a.m.

Title:	The PERCEPTA Registry: A Prospective Registry to Evaluate Percepta Bronchial Genomic Classifier Patient Data (Board #908)
Presenter:	D. Kyle Hogarth, M.D. (University of Chicago)
Date/Time:	Wednesday, October 26, 1:30-2:30 p.m.

* All times are Pacific Daylight Time (PDT)

In addition, during a private event scheduled for Monday, October 24, Fernando J. Martinez, M.D. (Weill Cornell Medical College) will present data supporting the advancement of Veracyte's Envisia classifier.

About Veracyte
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma[®] Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for 185 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In 2015, the company launched the Percepta[®] Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer, which has already received draft Medicare coverage. In the fourth quarter of 2016, Veracyte plans to launch its second pulmonology product, the Envisia™ Genomic Classifier, to improve diagnosis of interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Cautionary Note Regarding Forward-Looking Statements

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/data-demonstrating-clinical-value-of-veracyte-genomic-tests-for-use-in-lung-cancer-and-ipf-to-be-presented-at-chest-annual-meeting-2016-300344055.html

SOURCE Veracyte

News Provided by Acquire Media